Monday, May 6, 2013

Crizotinib (trade name Xalkori,[1] Pfizer), is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.[2]WIKIPEDIA

CONCEPTUALLY, THROUGH ITS PTPN6 ACTIVITY, THIS DRUG SHOULD HAVE SIGNIFICANT JAK-2 ACTIVITY AND SHOULD THEREFORE HAVE A ROLE IN MYELOPROLIFERATIVE DISORDERS THAT HAVE JAK-2 POSITIVITY, AND IN FACT THROUGH THE SAME, IT HAS EFFECT ON THE ERYTHROPOIETIN RECEPTOR!
Post a Comment